Recommended Pages at genengnews.com
GEN | News Highlights: IFITM3 Variant Linked with Worse Flu Symptoms, Need for Hospitalization
genengnews.com — “IFITM3 protein found to play critical role in restricting viral replication in vivo.” View full resource at genengnews.com
Most Recently Shared on March 26, 2012 at 2:11 pm By:
Richard G. Lanzara Health Professional
IFITM3 Variant Linked with Worse Flu Symptoms, Need for Hospitalization http://t.co/dsFdBJYu via @genbio #health #medicine
GEN | News Highlights: NicOx Pays £2M for 11.8% Stake in Ophthalmology Firm Altacor
genengnews.com — “Firm plans to generate a global business through acquisitions and licensing deals.” View full resource at genengnews.com
Most Recently Shared on March 23, 2012 at 3:00 pm By:
Luca M. Sergio Health Social Media and Health Executive
NicOx Pays £2M for 11.8% Stake in Ophthalmology Firm Altacor and Retains Buy #ophthalmology http://t.co/Jw2EtDDK
GEN | News Highlights: Cytos to Secure up to CHF 37M to Advance Phase II Asthma Immunotherapy
genengnews.com — “Firm will also leverage funding to progress other Immunodrug candidates in its pipeline.” View full resource at genengnews.com
Most Recently Shared on March 21, 2012 at 6:49 pm By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Cytos to Secure up to CHF 37M to Advance Phase II Asthma Immunotherapy http://t.co/2SfnpOUP
GEN | News Highlights:New Target and FDA-Approved Cholesterol-Lowering Drug Identified for HCV Therapy
genengnews.com — “NPC1L1 is required for HCV to gain entry into cells; NPC1L1-inhibitor ezetimibe delays infection in mouse models.” View full resource at genengnews.com
Most Recently Shared on January 27, 2012 at 7:07 pm By:
Nature Medicine Science Enthusiast
FDA-approved cholesterol-lowering blocks HCV cell entry: http://t.co/yY6gnZcw
GEN | Insight & Intelligence™: R&D Direction in 2012 for Sequencing Technologies Is Aimed at Clinical Medicine
genengnews.com — “Companies are focused on making these platforms smaller and easier to use.” View full resource at genengnews.com
Most Recently Shared on January 6, 2012 at 9:50 pm By:
Rebecca Hemenway Health Marketing
No surprises. R&D in 2012 for sequencing technologies is aimed at clinical medicine http://t.co/KDiZO2Gr #clinseq #personalizedmedicine
FDA Holds Public Discussion of User Fee Program for Biosimilars http://t.co/FRC0mBy2 #diabetes
genengnews.com — “FDA Holds Public Discussion of User Fee Program for Biosimilars http://t.co/FRC0mBy2 #diabetes” View full resource at genengnews.com
Most Recently Shared on December 17, 2011 at 1:54 am By:
FDA Holds Public Discussion of User Fee Program for Biosimilars http://t.co/FRC0mBy2 #diabetes
GEN | Analysis & Insight: Congressional Leaders Expect to Give Personalized Medicine Act Another Shot
genengnews.com — “Bill has not made it past committees on four prior occasions, but Rep. Eshoo would like to introduce a new version early next year.” View full resource at genengnews.com
Most Recently Shared on November 11, 2011 at 3:11 pm By:
Rebecca Hemenway Health Marketing
Congressional leaders, lead by @RepAnnaEshoo, expect to give #personalizedmedicine act another shot http://t.co/xiqKAIlb
GEN | News Highlights:Dermira Raises $42M in Series A and Acquires Dermatology Therapeutics Firm Valocor
genengnews.com — “Newly formed Dermira will continue development of clinical-stage PDT for acne and preclinical topical acne and inflammatory skin disease candidates.” View full resource at genengnews.com
Most Recently Shared on October 21, 2011 at 11:43 am By:
Dermira raises $42M in series A, acquires dermatology therapeutics firm Valocor. http://t.co/E2xijIF8
GEN | News Highlights: Illumina Leads $8M Financing Round for GenoLogics
genengnews.com — “Earlier this year GenoLogics entered a collaboration with and launched a new LIMS software for Illumina.” View full resource at genengnews.com
Most Recently Shared on October 20, 2011 at 7:08 pm By:
Rebecca Hemenway Health Marketing
Illumina leads $8M financing round for GenoLogics http://t.co/marPoZhh LIMS and #clinical apps
To aid in search of a #melanoma cure, NIH gives Genesis Biopharma Access to 43 Cancer Cell Therapy Patents for $1.2M http://t.co/M0wOwOZo
genengnews.com — “To aid in search of a #melanoma cure, NIH gives Genesis Biopharma Access to 43 Cancer Cell Therapy Patents for $1.2M http://t.co/M0wOwOZo” View full resource at genengnews.com
Most Recently Shared on October 11, 2011 at 10:10 pm By:
Melanoma Research Oncology, Dermatology, and Health Organization
To aid in search of a #melanoma cure, NIH gives Genesis Biopharma Access to 43 Cancer Cell Therapy Patents for $1.2M http://t.co/M0wOwOZo
GEN | News Highlights: BARDA Provides $56.3M to Support Five Drugs Against Radiation Injury
genengnews.com — “Contracts will go toward small molecule, peptide, protein, and cell-based therapies.” View full resource at genengnews.com
Most Recently Shared on September 29, 2011 at 2:55 pm By:
Drugs and Devices OW OW Health
BARDA Provides $56.3M to Support Five Drugs Against Radiation Injury - Genetic Engineering News: BARDA Pro... http://t.co/6DG228sd #drug
GEN | BLOGbiotech: Improving Healthcare Delivery: Over the Counter and Under the Radar
genengnews.com — “GEN | BLOGbiotech: Improving Healthcare Delivery: Over the Counter and Under the Radar” View full resource at genengnews.com
Most Recently Shared on August 27, 2011 at 5:30 pm By:
RT @healthnewspr: Improving Healthcare Delivery: Over the Counter and Under the Radar http://t.co/KyLkfQf #health
GEN | News Highlights:Cytos Makes 80% Workforce Cut and Halts All In House Programs Except Lead Allergy Drug
genengnews.com — “Firm will focus on Phase II-stage Cyt003-QbG10 candidate and continue with Pfizer and Novartis-partnered programs.” View full resource at genengnews.com
Most Recently Shared on August 17, 2011 at 11:34 am By:
John Carroll Health Communicator
Cytos hits the wall; laying off most of its workers, circling wagons on lead program. http://t.co/KV8e8mp
GEN | Analysis & Insight:U.S. Stem Cell Companies Find Partners and Revenues Beyond the Water’s Edge
genengnews.com — “Firms find it easier to navigate regulatory requirements in Asia as well as Europe.” View full resource at genengnews.com
Most Recently Shared on August 16, 2011 at 4:51 pm By:
GEN | Analysis & Insight:U.S. Stem Cell Companies Find Partners and Revenues Beyond the Water’s Edge: http://t.co/h50A1xo
GEN | News Highlights: Scientists Demonstrate that Astrocytes from Both Familial and Sporadic ALS Are Toxic to Motor Neurons
genengnews.com — “Research suggests SOD1 represents a therapeutic target in commonest form of neurodegenerative disease.” View full resource at genengnews.com
Most Recently Shared on August 15, 2011 at 3:40 pm By:
Pete Shuster Promotional and Health Business Administrator
GEN News: Scientists Demonstrate Astrocytes from Both Familial & Sporadic ALS Are Toxic to Motor Neurons: http://t.co/Z8oq1D9 via @addthis
